CUBE ANNOUNCES ACQUISITION OF LEADING AI OPERATIONAL RISK PROVIDER, ACIN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Femasys Revenue Jumps 85 Percent in Q2
Key Points Revenue surged 84.8% to $0.41 million (GAAP) in Q2 2025, far outpacing consensus estimates (GAAP) but still early-stage in scale. FemBloc gained its first-ever European approval; FemaSeed and FemVue secured new regulatory clearances and partnerships. Net loss (GAAP) narrowed slightly to $4.59 million, while cash reserves (GAAP) dropped to $3.22 million, bringing a near-term cash crunch. These 10 stocks could mint the next wave of millionaires › Femasys (NASDAQ:FEMY), a women's health medical technology firm developing permanent birth control and fertility solutions, released its second quarter 2025 results on August 8, 2025. The earnings report was marked by strong revenue growth to $0.41 million (GAAP)—an 84.8% jump in GAAP sales from the prior year period—driven by accelerating early-stage sales of FemaSeed intratubal insemination devices and FemVue diagnostic systems. This figure (GAAP revenue of $409,268) came in far above analyst estimates. The company posted a GAAP net loss of $4.59 million, a slight improvement from the $4.68 million GAAP net loss in Q2 2024. Diluted earnings per share (GAAP) was slightly better than analyst estimates at $(0.16). Despite clear commercial and regulatory progress, continued operating losses and a $3.22 million cash balance as of June 30, 2025 mean Femasys will need additional funding within the next quarter to sustain operations. Source: Analyst estimates for the quarter provided by FactSet. Femasys at a Glance and Business Focus Femasys designs and commercializes non-surgical products for women's reproductive health needs. Its main portfolio spans permanent birth control devices—most notably the FemBloc system—and fertility-related solutions like FemaSeed and FemVue. Recent company focus has been on winning new regulatory approvals, especially for FemBloc, and moving early-stage products from research and development into wider commercial sales. Key success factors for Femasys include clearing regulatory hurdles in each market, gaining adoption from clinics and patients, and forming the right distribution partnerships. Protecting its intellectual property is also essential given the specialized nature of its technology. Quarter Highlights: Financial and Product Progress Revenue (GAAP) climbed 84.8%, driven by sales of FemaSeed and FemVue. A roughly $400,000 order from Spain signals a pivotal step in international expansion efforts. Sales of FemaSeed intratubal insemination devices and FemVue diagnostic products—tools that facilitate fertility assessment—drove most of the top-line gain. Together, these products represent the company's early moves beyond the U.S. market. On the regulatory front, Femasys achieved a series of important clearances: FemBloc received its first European approval, marking the first global regulatory sign-off for a non-surgical permanent birth control option in the company's portfolio. FemaSeed and FemVue also gained approvals in Australia and New Zealand, expanding potential markets and laying groundwork for future sales. Ongoing enrollment in U.S. pivotal trials for FemBloc continues, which will be crucial for future coverage and adoption in the American healthcare market. The company expanded its reach through new partnerships. It announced a relationship with the Carolinas Fertility Institute, an eight-clinic network in the U.S, to offer FemaSeed to more patients. Distribution partnerships in Spain will support further commercialization of FemBloc. Femasys also shored up its patent portfolio, receiving notice of intent to grant new patents in Europe and the U.S. for FemBloc and FemaSeed, maintaining its lead in the emerging non-surgical device category. Financially, the net loss (GAAP) narrowed slightly to $4.59 million, reflecting both increased sales and a 28.4% drop in research and development expense as products transition to the commercial phase. However, cash burn remained high: the $3.22 million cash balance at June 30, 2025 gives the company only enough runway to operate into early fourth quarter, without additional funding. The company raised $4.5 million in new equity but continued operating losses have quickly reduced available resources. Inventory increased 71.8% year-to-date (as of June 30, 2025), showing strategic preparation for expected sales but also a concentration of capital in unsold goods. The share count rose from 23,355,926 as of December 31, 2024, to 32,575,407 as of June 30, 2025. Femasys does not currently pay a dividend. Looking Forward Femasys management did not provide specific revenue or earnings targets for the coming quarters or for fiscal 2025. Leadership emphasized that the next stages will focus on translating recent approvals and pilot orders into routine commercial adoption, particularly in the European Union and new Asia-Pacific markets, and continuing to build distribution and clinic partnerships. Given the current cash position as of June 30, 2025, the company expects its cash and cash equivalents will be sufficient to fund operations into the early fourth quarter of 2025. The expanding international footprint and product pipeline, along with progress on intellectual property protection, remain important areas for investors to monitor in the coming periods. FEMY does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,047%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
CTV News
a day ago
- CTV News
Canada will lower price cap for Russian oil
Finance Minister Francois-Phillippe Champagne along with the Foreign Affairs Minister Anita Anand are seen in this image. The federal government has announced it will lower the price cap for Russian-origin crude oil to US$47.60 per barrel, down nearly $13 from the previous $60 per barrel, in an effort to restrict Russia's war efforts against Ukraine. Finance Minister Francois-Phillippe Champagne along with the Foreign Affairs Minister Anita Anand announced the measure in a press release on Friday, saying Canada, alongside with the EU and the U.K. have taken a stand against Russia's 'unjust and unprovoked war' against Ukraine. 'The lower price cap will weaken Russia's ability to fund its illegal war and exert renewed pressure on Putin's military apparatus,' the Department of Finance's statement said. 'By further lowering the price cap on Russian crude oil, Canada and its partners are ratcheting up the economic pressure and limiting a crucial source of funding for Russia's illegal war,' Champagne said in the statement. 'Our government has been a steadfast ally to Ukraine, and we will continue to support them in defending their territorial integrity, sovereignty, and peace for its people.' According to the statement, this strategy will also safeguard any future price caps that may be implemented by Canada. 'Canada has stood, and will continue to stand, with Ukraine and its brave people as they defend their sovereignty against Russia's illegal invasion,' Anand's statement read. 'Beyond the many direct supports Canada has provided in Ukraine's defence, we also continue to apply pressure on Russia as well as deny its means to fund the ongoing war.' The coalition includes all the G7 countries, along with Australia and New Zealand, who are aiming to restrict Russia's ability to fund the war by capping the price of Russian oil, according to the statement. The price cap on seaborne Russian-origin crude oil was first implemented on Dec. 2, 2022, after Russia invaded Ukraine. Meanwhile, U.S. President Donald Trump has announced that he will be meeting Russian President Vladimir Putin to discuss the war in Ukraine shortly, after imposing additional sanctions on Russia and tariffs on countries that purchase Russian oil. The changes in the price aim to exert extra pressure on Putin's military efforts and will come into play during the coming weeks. Canada's ban on direct Russian oil imports from March 2022 remain in effect. With files from the Associated Press
CTV News
a day ago
- CTV News
Canadian researchers have an eye on the sky, tracking contrails with cameras
Using a camera network, the researchers are tracking contrails to mitigate aviation-induced climate change. CTV London's Reta Ismail has the story. Researchers at Western University are tackling aviation-induced climate change – by using existing cameras to track contrails. They're called contrails short for condensation trails, visible in the sky. And according to scientists, these thin white trails impact the environment. 'Aviation is a significant source of climate change impact and a portion of that is not direct CO2 emissions, but the secondary effects that come from contrails,' said Denis Vida, a physics and astronomy professor at Western University. To mitigate the impact of contrails, a team of researchers from Western, along with the Global Meteor Network (GMN), is working with an experienced pilot to change the flying altitude of planes by using ground-based cameras to observe airplanes. 'Small percentage of flights, about 15 per cent, would need to make little corrections just in height that don't cost much to eliminate contrails entirely,' explained Vida. 'The major problem is that, there's no data to inform the models to send the airplanes in the right direction, and we're changing that with our project.' The project is now financially backed by Google and Breakthrough Energy. Vida founded and now coordinates GMN, a game-changing international collaboration that has more than 1,400 cameras globally to capture meteor events and now survey aircraft contrails. This project started after Luc Busquin, an experienced captain with Alaska Airlines and founder of ContrailCast, reached out to Vida about using a GMN meteor camera to observe contrails for climate impact research. 'This solution was answering a need from the contrails researchers that they needed to be able to associate contrails with flights, but they were not able to do. And this solution was an answer to the problem,' said Busquin. Vida says existing geostationary satellite systems on average only detect contrails 30 minutes after formation, limiting their utility for actionable mitigation strategies. GMN, with its global distribution of calibrated cameras that directly observe contrails as they are created, offers a unique opportunity. By the end of the year, the team hopes to deliver the first open-access dataset linking contrails with flights and atmospheric conditions. This will give air traffic controllers and various other stakeholders relevant information to re-organize the flow of flight patterns and create real change in future aircraft designs and technologies.
